enzh-TWfrdeitjaptrues

Latest Bing Center News

New Waldenstrom Macroglobulinemia Patient Story of Hope

New Waldenstrom Macroglobulinemia Patient Story of Hope

Peter DeNardis was diagnosed with Waldenstrom macroglobulinemia in 2003 and is a board member for the International Waldenstrom’s Macroglobulinemia Foundation (IWMF). He shares his personal story of living with Waldenstrom and explains how new treatments for Waldenstrom macroglobulinemia are evolving. He also shares why patients who have this rare cancer can finally be hopeful about the future.

Read more..

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana-Farber/Brigham and Women’s Cancer Center is ranked the best in New England

Dana Farber/Brigham and Women’s Cancer Center has been recognized as a Best Hospital for 2020-21 by U.S. News & World Report.  For the 20th straight year, Dana-Farber/Brigham and Women’s Cancer Center is ranked as the best hospital for cancer care in New England and is ranked #6 in the nation this year.

Read more..

IWMF Virtual Educational Forum August 27-28, 2020

IWMF Virtual Educational Forum August 27-28, 2020

Join us at the 2020 IWMF Virtual Educational Forum -  a unique opportunity to come together and learn from medical experts and WM community members around the world – all from the comfort of your own home! Experience our 2020 Vision: A World Without WM.

Read more..

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for the treatment of Waldenström macroglobulinemia (WM).

Read more..

The IWMF announces $800,000 in new research funding

The IWMF announces $800,000 in new research funding

The IWMF Board of Trustees has approved $800,000 in new research support for two research projects from the IWMF-LLS (Leukemia & Lymphoma Society) Strategic Research Roadmap initiative.

Read more..

Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!

Lu Kleppinger: Therapy Round Two- Ibrutinib, the Freedom of a Pill!

After undergoing eighteen months of chemotherapy ending in 2014, which resulted in much success and years of being well managed and free of infusions, my WM flared up again, significantly, in 2019.  This required me to go back into treatment.

Read more..

WM and COVID-19: WMUK Webinar Recordings

WM and COVID-19: WMUK Webinar Recordings

On Friday 19 June, over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom's macroglobulinaemia (WM).

Read more..

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM

Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.

Read more..

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application ...

Read more..

COVID-19 & Hematologic Malignancies: Patient Experience Update

COVID-19 & Hematologic Malignancies: Patient Experience Update

We are excited to announce this new webcast focusing on the experience of patients undergoing treatment for hematologic malignancies during the COVID-19 era.

Read more..